Trials / Completed
CompletedNCT01477411
A Drug-Drug Interaction Study of Digoxin and PA21
A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Digoxin in Healthy Male and Female Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Vifor Pharma · Industry
- Sex
- All
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine if Digoxin is affected by PA21.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PA21 | The maximum dose of PA21 will be 15.0 g/day. |
| DRUG | Digoxin | The maximum dosage of Digoxin will be 0.5 mg/day |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-01-01
- Completion
- 2012-01-01
- First posted
- 2011-11-22
- Last updated
- 2012-01-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01477411. Inclusion in this directory is not an endorsement.